Biochemical alterations to tau (as happens in Alzheimer’s disease and other tauopathies) could further modulate the barrier properties in the AIS, with significant implications for missorting of tau to the somatodendritic compartment and neurodegeneration. This evidence concerns the gene MAPT and tauopathy.